521064-34-6 Usage
Uses
Used in Pharmaceutical Industry:
N-(4-Bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine is utilized as a key intermediate in the synthesis of pharmaceutical compounds for its potential to contribute to the development of new drugs. Its unique molecular structure allows for specific interactions with biological targets, which can be leveraged to create medications with novel mechanisms of action.
Used in Chemical Industry:
In the chemical industry, N-(4-Bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine serves as a building block for the creation of various chemical products. Its bromine and chlorine atoms, in particular, may be involved in reactions that lead to the formation of new compounds with specialized applications, such as in agrochemicals, dyes, or advanced materials.
Used in Research and Development:
N-(4-Bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine is employed as a subject of study in research and development labs. Scientists explore its chemical reactivity, potential applications, and interactions with biological systems to uncover new uses and optimize its synthesis for industrial applications. This research is crucial for advancing the understanding of its properties and expanding its utility in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 521064-34-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,2,1,0,6 and 4 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 521064-34:
(8*5)+(7*2)+(6*1)+(5*0)+(4*6)+(3*4)+(2*3)+(1*4)=106
106 % 10 = 6
So 521064-34-6 is a valid CAS Registry Number.
521064-34-6Relevant academic research and scientific papers
Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2
Poirier, Marion,Awale, Mahendra,Roelli, Matthias A.,Giuffredi, Guy T.,Ruddigkeit, Lars,Evensen, Lasse,Stooss, Amandine,Calarco, Serafina,Lorens, James B.,Charles, Roch-Philippe,Reymond, Jean-Louis
supporting information, p. 224 - 236 (2018/12/13)
By screening a focused library of kinase inhibitor analogues in a phenotypic co-culture assay for angiogenesis inhibition, we identified an aminotriazine that acts as a cytostatic nanomolar inhibitor. However, this aminotriazine was found to be completely inactive in a whole-kinome profiling assay. To decipher its mechanism of action, we used the online target prediction tool PPB2 (http://ppb2.gdb.tools), which suggested lysophosphatidic acid acyltransferase β (LPAAT-β) as a possible target for this aminotriazine as well as several analogues identified by structure–activity relationship profiling. LPAAT-β inhibition (IC50 ≈15 nm) was confirmed in a biochemical assay and by its effects on cell proliferation in comparison with a known LPAAT-β inhibitor. These experiments illustrate the value of target-prediction tools to guide target identification for phenotypic screening hits and significantly expand the rather limited pharmacology of LPAAT-β inhibitors.
